Organisation paid for research Program year 2025 Source: CMS Open Payments

Long Beach Research Institute

Neither a doctor nor a teaching hospital

Research payments

$5,177,028

1,002 payments

Through program year 2025, Long Beach Research Institute is reported as receiving $5,177,028 in research payments, across 1,002 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $2,927,369 292
2024 Research $1,890,241 335
2023 Research $338,726 181
2022 Research $20,692 194

Breakdown

Who paid Research payments · program years 2022–2025
  1. Vertex Pharmaceuticals Incorporated $1,501,146 4 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,222,269 73 payments
  3. Moderna TX, Inc. $624,612 65 payments
  4. Sumitomo Pharma America, Inc. $576,732 89 payments
  5. Amgen Inc. $475,351 11 payments
  6. Seqirus USA Inc $212,770 89 payments
  7. Alnylam Pharmaceuticals Inc. $189,425 443 payments
  8. Jazz Pharmaceuticals Inc. $164,674 186 payments
  9. Tolmar, Inc. $50,480 17 payments
  10. Sun Pharmaceutical Industries Inc. $46,845 5 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $1,277,526 2 payments
  2. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $1,128,690 56 payments
  3. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $534,959 33 payments
  4. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $266,148 25 payments
  5. A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $222,153 1 payment
  6. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $208,411 87 payments
  7. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $187,235 395 payments
  8. VOYAGER P3 AD Vaccine Study $179,984 2 payments
  9. OUTPOST Clinical Home Use Study $133,862 2 payments
  10. ASCEND P3 AD Extension $128,416 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record